Phase Ib Trial of MPDL3280A with Bevacizumab or with Bevacizumab + FOLFOX in Patients with Solid Tumors

Conditions

Colon | Lung | Rectum

What is the purpose of this trial?

The purpose of this study is to find the best dose, and what affects, good and/or bad, and experimental drug (MPDL3280A) has when used in combination with bevacizumab and with bevacizumab plus FOLFOX chemotherapy to treat subjects with locally advanced or metastatic solid tumors.


Participation Guidelines

Age:
18 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Genentech, Inc.
Dates:
10/07/2013
Last Updated:
Study HIC#:
1306012219